The US CDC has updated the areas at risk for chikungunya on 16 April 2026 (Cuba no longer outbreak country). In addition, the Swiss Expert Committee for Travel Medicine assessed the risk for Mauritius, Argentina and French Guinea, (red = changes compared to last update 10 March2026):

Chikungunya is showing a strong increase, with 1’415 cases recorded since the beginning of the year, with a daily average of 50-40 infections. Currently, 148 cases are active.

The current outbreak represents a resurgence of chikungunya transmission in Mauritius following the 2025 epidemic. 

Argentina: A sharp rise in chikungunya activity has been reported since February. Around 750 new locally acquired cases have been confirmed, with more than 5’500 suspected cases nationwide through week 14, marking a significant increase above average levels. Most cases are concentrated in the northwestern provinces of Salta, Tucumán, and Jujuy.

French Guiana: Since the first case of chikungunya was detected in late January 2026, 85 locally acquired cases have been reported (+20 cases within the past four weeks).

Suriname: Between 1 January and mid-March, 2’579 chikungunya virus disease cases have been reported of which 1’354 were confirmed. Since January 2026, one EU Member State also observed a marked increase in detections of chikungunya virus among returning travelers from Suriname and Paramaribo in particular.

As of 28 March 2026, Bolivia has reported 1’168 Zika cases since the start of the year, a sharp increase compared with 130 cases in the same period in 2025. This figure is already approaching the total of 1’224 cases recorded for the whole year 2025.

The Western Australia Department of Health has issued a clinical alert after reporting 34 cases this year, with 29 cases concentrated in the Kimberley region. Both cutaneous and respiratory infections have been identified, with respiratory cases marking the first in over 50 years.

France reported a total of 11 travel associated ZIKV cases linked to Indonesia between July 2025 and March 2026, including four cases detected in early 2026. Most cases were associated with travel to Bali and neighboring islands. All cases were laboratory confirmed, and Asian lineage was identified in sequenced samples.

Despite high and increasing travel volumes from Indonesia to the EU/EEA since 2022, no corresponding increase in imported ZIKV cases has been observed by other EU/EEA countries.

As of March 2026, mpox transmission continues globally across all clades, with clade Ib now confirmed for the first time in Argentina, Ecuador, Austria, the Central African Republic, Russia and Singapore and community transmission documented in five European countries (Austria, Belgium, Portugal, Spain, and the UK).

Sustained community transmission in Madagascar (clade Ib), Pakistan.

DRC Ministry of Health officially declares the end of the mpox epidemic as a national public health emergency on April 2, 2026.

A recombinant clade Ib/IIb strain has been detected in two travelers, with evidence suggesting wider circulation than currently documented (see WHO).

End of March, EMA’s committee for human medicines has issued a recommendation that Tecovirimat SIGA should not longer be used for the treatment of mpox (see EMA).


See also WHO global trends.

High transmission in Indonesia, the United States, Canada, Peru (Puno), Bangladesh, Japan (Tokyo), and Philippines.  

Also continued high transmission in Mexico, Guatemala, Kazakhstan, Liberia, Yemen, UK (Birmingham) and Latvia.

Resurgence of cases, with approximately 28 000 cases reported in weeks 1–10 of 2026, are occuring during the seasonal transmission peak but exceeding typical endemic patterns, driven in part by favorable environmental conditions.
See also www.healthytravel.ch February and March 2026.